Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development

Andrew C. Hsieh; Eric J. Small; Charles J. Ryan

doi:10.1016/S1470-2045(07)70316-9

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development

Andrew C. Hsieh, Eric J. Small, Charles J. Ryan

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

Many attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.

Original language	English (US)
Pages (from-to)	933-939
Number of pages	7
Journal	Lancet Oncology
Volume	8
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(07)70316-9
State	Published - Oct 1 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/S1470-2045(07)70316-9

OpenUrl availability

Full text

Cite this

@article{b844c6df65834950be03f91412090bd0,

title = "Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development",

abstract = "Many attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.",

author = "Hsieh, {Andrew C.} and Small, {Eric J.} and Ryan, {Charles J.}",

year = "2007",

month = oct,

day = "1",

doi = "10.1016/S1470-2045(07)70316-9",

language = "English (US)",

volume = "8",

pages = "933--939",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Androgen-response elements in hormone-refractory prostate cancer

T2 - implications for treatment development

AU - Hsieh, Andrew C.

AU - Small, Eric J.

AU - Ryan, Charles J.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Many attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.

AB - Many attempts have been made to derive genetic signatures for progressive prostate cancer for both prognostic and therapeutic purposes. These investigations have resulted in the discovery of many pathways, but the signatures exhibit heterogeneity and restricted reproducibility. A thorough and disciplined analysis of genes with androgen-response elements that are expressed in progressive, castration-resistant prostate cancer is an integral step towards the development of new therapeutic or diagnostic targets. We discuss the effects of bona-fide downstream targets of the androgen receptor on cellular proliferation, evasion of apoptosis, and angiogenesis, and consider the clinical potential of these targets.

UR - http://www.scopus.com/inward/record.url?scp=34748912386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748912386&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(07)70316-9

DO - 10.1016/S1470-2045(07)70316-9

M3 - Review article

C2 - 17913662

AN - SCOPUS:34748912386

SN - 1470-2045

VL - 8

SP - 933

EP - 939

JO - Lancet Oncology

JF - Lancet Oncology

IS - 10

ER -

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this